With 61948.0 shares changed hands, the volume of the stock remained heavier than its average volume of 45370.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.23 whereas the lowest price it dropped to was $1.15. The 52-week range on ANEB shows that it touched its highest point at $3.42 and its lowest point at $0.90 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at -0.86.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ANEB was down-trending over the past week, with a drop of -49.15%, but this was down by -49.29% over a month. Three-month performance dropped to -50.82% while six-month performance fell -15.49%. The stock lost -28.57% in the past year, while it has gained 21.21% so far this year.
Float and Shares Shorts:
At present, 41.08 million ANEB shares are outstanding with a float of 24.43 million shares on hand for trading. On 2025-11-28, short shares totaled 0.12 million, which was 30.0 higher than short shares on 1761868800. In addition to Dr. Joseph F. Lawler M.D., Ph.D. as the firm’s Founder & Chairman, Mr. Richard Anthony Cunningham serves as its CEO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, ANEB reported revenue of $0.0 and operating income of -$2250435.0. The EBITDA in the recently reported quarter was -$2140915.0 and diluted EPS was -$0.05.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ANEB since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. The surprise factor in the prior quarter was -$0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.14 and the low estimate is -$0.14. The average estimate for the next quarter is thus -$0.14.
